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Although induction immunochemotherapy including high-dose cytarabine and rituximab followed by high-dose chemotherapy (HDC) with autologous stem cell transplantation (ASCT) is recommended for younger patients (≤65 years old) with untreated mantle cell lymphoma (MCL), no standard induction and HDC regimen has been established. We conducted a phase II study of induction immunochemotherapy of R-High-CHOP/CHASER followed by HDC of LEED with ASCT in younger patients with untreated advanced MCL. Eligibility criteria included untreated MCL, stage II bulky to IV, and age 20-65 years. Patients received 1 cycle of R-High-CHOP followed by 3 cycles of CHASER every 3 weeks. Peripheral blood stem cells (PBSC) were harvested during CHASER. LEED with ASCT was delivered to patients who responded to R-High-CHOP/CHASER. Primary endpoint was 2-year progression-free survival (PFS). From June 2008 to June 2012, 45 patients (median age 59 years; range 38-65 years) were enrolled. PBSC were successfully harvested from 36 of 43 patients. Thirty-five patients completed ASCT. Two-year PFS was 77% (80% CI 68-84), which met the primary endpoint. Five-year PFS and overall survival were 52% (95% CI 34-68%) and 71% (95% CI 51-84%), respectively. Overall response and complete response rates after induction immunochemotherapy were 96% and 82%, respectively. The most common grade 4 toxicities were hematological. In younger patients with untreated MCL, R-High-CHOP/CHASER/LEED with ASCT showed high efficacy and acceptable toxicity, and it can now be considered a standard treatment option.
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| INTRODUCTION
Mantle cell lymphoma (MCL) is a well-recognized B-cell lymphoma subtype that accounts for approximately 5% of all patients with NHL. 1 The clinical course of MCL ranges from indolent to aggressive, with a poor prognosis and a median OS of about 3-5 years with conventional chemotherapy. 2, 3 The prognosis when using conventional chemoimmunotherapy remains poor. Two-year PFS of 30% was reported in a phase II study of MCL patients treated with 6 cycles of rituximab, an anti-CD20 antibody, and CHOP chemotherapy. 4 However, a randomized phase III study by the European MCL Network that compared myeloablative radiochemotherapy followed OGURA ET AL.
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by ASCT with interferon-α (IFN-α) maintenance during the first remission after a CHOP-like regimen demonstrated significant superiority of ASCT, with PFS of 45% in younger patients aged 65 years or less in patients with advanced-stage MCL. 5 Promising approaches to improving CR rate before ASCT, as well as PFS and OS, include modified induction therapy with HDAC-based chemotherapy regimens and rituximab. These strategies are based on clinical studies in which the addition of rituximab to an HDAC-containing regimen was reported to ensure tumor depletion in vivo while allowing the collection of PBSC with conserved engraftment capability that was devoid of tumor cells. 6, 7 A phase II MCL-2 study by the Nordic Lymphoma Group including HDAC and rituximab prior to stem cell mobilization, followed by HDC and ASCT, demonstrated an excellent ORR (96%), with a CR rate of 56%, and PFS of 70% and OS of 70% after 6 years. 8 Similar promising results were also reported in another phase II study of an induction regimen with R-CHOP and R-DHAP followed by ASCT, which was conducted by GELA. 9 This regimen of 6 cycles of alternating R-CHOP/R-DHAP followed by consolidative HDC with ASCT resulted in a superior PFS compared with the regimen of 6 cycles of R-CHOP followed by consolidative HDC with ASCT reported for a randomized phase III study by the European Mantle Cell Network (European MCL Network). 10 Recently, rituximab maintenance after ASCT was shown to improve event-free survival, PFS, and OS in younger patients with MCL in a randomized phase III study by LYSA. 11 Thus, HDC with ASCT after intensive immunochemotherapy using rituximab and HDAC as first-line treatment, followed by rituximab maintenance, appears to be the only current therapy that might improve the outcomes of younger patients with untreated advanced MCL. [10] [11] [12] However, there was no established regimen for induction and HDC when the present study was planned.
We developed the R-High-CHOP/cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab (CHASER) regimen as an induction therapy, and LEED therapy as HDC. One cycle of the R-High-CHOP regimen was incorporated to enhance MCL tumor reduction. CHASER and CHASE were originally developed for both salvage therapy without a platinum agent to avoid renal toxicity and for in vivo efficacy of purging of B-cell lymphoma cells during harvesting of autologous PBSC. 13, 14 Based on promising data from a small pilot study of R-High-CHOP/CHASER/LEED in newly diagnosed MCL in a single institute of the Aichi Cancer Center (data not shown), we conducted a phase II study (JCOG0406) of this regimen using a new induction procedure comprising R-High-CHOP/CHASER 13,14 with rituximab and HDAC followed by HDC (LEED therapy) with ASCT.
| MATERIALS AND METHODS

| Trial information
This trial was a multi-institutional phase II study conducted by JCOG-LSG. The study protocol was approved by the Protocol Review Committee of JCOG and by the respective institutional review boards.
Written, informed consent was obtained from each patient before enrolment in accordance with the Declaration of Helsinki.
The trial is registered with the UMIN Clinical Trials Registry (UMIN000001220). 
| Eligibility criteria
| Treatment
The 
| Central pathology review
A central pathology review was carried out as previously reported. 16 Antigens routinely examined by immunohistochemistry included CD3, CD5, CD10, CD20, cyclin D1, SOX-11, Ki-67, and cyclin D1.
Four hematopathologists reviewed the pathology specimens and classified them according to the WHO classification system 2001. 15 The diagnosis by the central pathology review committee was used in this article. 
| Mantle cell lymphoma international prognostic index (MIPI) and modified combination of the Ki-67 index and MIPI (MIPI-c)
| Statistical analysis and endpoints
Primary endpoint was 2-year PFS. Planned sample size was 45, with an expected 2-year PFS of 50%, a threshold of 30%, 1-sided α of CI were estimated by an exact binomial method. OS and PFS were estimated according to the Kaplan-Meier method, and CI were estimated by Greenwood's formula. These analyses were carried out using SAS release 9.2 (SAS Institute, Cary, NC, USA). 
| RESULTS
| Patient characteristics
| Feasibility
| Responses
Responses of the 45 enrolled patients are shown in Table 2 
| Progression-free survival
Median follow-up time for all enrolled patients was 3.7 years in the primary analysis. Two-year PFS as the primary endpoint of all enrolled patients was estimated to be 77.3% (lower boundary of 80% CI 68.0%, which exceeded the threshold of 30%, and 95% CI 61.9-87.1%), which met the primary endpoint ( Figure 3A ). PFS at 5 years was estimated to be 52.2% (95% CI 33.8-67. 
| Overall survival
Overall survival of all 45 enrolled patients is shown in Figure 4A .
Eleven patients died (7 died of MCL, 3 died of secondary malignancy Figure 4B ,C, respectively. OS rates at 5 years for patients who received LEED therapy followed by ASCT (n = 35) and for patients who did not receive LEED therapy followed by ASCT for any reason including harvesting failure of PBSC (n = 10) were 71.9% (95% CI 47.4-86.4%) and 67.5% (95% CI 29.1-88.3%), respectively.
MIPI-c is shown in
| Toxicity
All 45 treated patients were evaluated for toxicity ( Table 3 ). The most common grade 4 toxicities were hematological; the percentage of patients with grade 4 neutropenia and thrombocytopenia was 80% and 0% in R-High-CHOP, 91% and 89% in CHASER, and 94%
and 77% in LEED, respectively. There were no grade 4 nonhematological or nonlaboratory toxicities during the entire protocol treatment. In R-High-CHOP therapy, 1 grade 4 increased alanine aminotransferase (ALT) was observed, and grade 3 increased aspartate aminotransferase (AST) and hyponatremia were observed in 1 patient each. All of these adverse events were reversible.
In CHASER therapy, grade 4 hypokalemia was observed in 1 patient, and grade 3 hyponatremia and hypokalemia were observed in 1 and 3 patients, respectively. All of these adverse events were reversible.
In LEED therapy, grade 4 hypokalemia was observed in 1 patient, and grade 3 increased AST, increased ALT, hyponatremia, and hypokalemia were observed in 2, 3, 1, and 5 patients, respectively. All of these adverse events were reversible. In the present study, 3 types of opportunistic infection were observed in 5 patients, including grade 3 Pneumocystis pneumonia in 2 patients, grade 3 cytomegalovirus infection in 2 patients, and grade 3 adenovirus cystitis in 2 patients; one patients 
| Pathological characteristics
A central review of the pathological diagnosis was carried out for 45
enrolled patients, and all were confirmed as having cyclin D1-positive MCL, although 1 patient was diagnosed as having CD5-negative MCL.
Although CD5 positivity was defined as an eligibility criterion in this study, the Central Pathology Review Committee decided that this patient was pathologically eligible, as CD5 negativity was not unequivocally confirmed by other techniques, including flow cytometry. The 5-year event-free survival in the GELA phase II study of 3 cycles of R-CHOP and 3 cycles of R-DHAP followed by ASCT was 64%. 9 In the randomized phase III study by the European MCL Network, the 5-year PFS in the experimental arm of 6 cycles of the alternating R-CHOP/R-DHAP regimen followed by consolidative HDC with ASCT and the control arm of 6 cycles of R-CHOP followed by consolidative HDC with ASCT was 65% and 44%, respectively. 10 The present results provide further data to support the treatment approach used in these prior studies. Combined with the present data, the present findings strongly suggest that HDAC-based high-dose consolidation therapy followed by ASCT has dramatically improved the prognosis of MCL compared with the Therefore, HDAC-based high-dose consolidation therapy followed by ASCT should be considered a standard treatment strategy for frontline treatment of younger MCL patients.
Recently, rituximab maintenance after ASCT was reported to improve event-free survival, PFS, and OS in younger patients with MCL. 11 PFS at 4 years was 83% in the rituximab maintenance group versus 64% in the observation group (P < .001), and OS was 89% vs 80% (P = 0.04), respectively. In this study, no patients received rituximab maintenance, and PFS and OS at 4 years were almost the same as in the observation group. It is likely that adding rituximab maintenance to our regimen will improve outcomes further.
In order that as many patients as possible can proceed to ASCT, it is important to achieve CR or PR after the induction chemotherapy before ASCT. In the present study, ORR and CR rates after RHigh-CHOP/CHASER induction therapy were 95.6% (95% CI 84.9-99.5%) and 82.2% (95% CI 68.0-92.0%), respectively. In the Nordic MCL-2 study, ORR and CR rates including uncertain CR were 96.3%
and 54.4%, respectively. 8 In the GELA phase II study, ORR and CR rates after induction therapy were 95% and 57%, respectively. 9 In the European MCL Network phase III study, ORR and the CR including unconfirmed CR rate after alternating R-CHOP/R-DHAP were 94% and 55%, respectively. 10 In a phase III LYSA study to evaluate the usefulness of rituximab maintenance treatment, induction therapy was 4 cycles of R-DHAP (6.7% of patients received an additional 3 cycles of R-CHOP), and ORR and CR rates were 94% and 74% (including 34% with unconfirmed CR), respectively. 11 Thus, the high CR rate of 82.2% in the present study is notable. Recently, retrospective data of a nationwide study of MCL in Japan were reported. 22 In that study, 501 patients with newly diagnosed MCL with a median age of 67 (range 22-90) years treated with rituximab-containing therapy between 1992 and 2012 were analyzed. PFS and OS at 5 years were 25% and 60%, respectively. These results are lower than in the present study (PFS of 52% and OS of 71% at 5 years). Although comparison is difficult, the most probable reason for these differences might be differences in the study populations: The median age was 67 years in the nationwide retrospective study and 59 years in the present study, and 48% of patients received R-CHOP without ASCT in the retrospective nationwide study, whereas all patients in the present study received treatment with the intent of ASCT.
In the present study, 22.2% of all enrolled patients did not receive ASCT, whereas in the Nordic MCL-2 study 6.8% of all 160 eligible patients did not proceed to the high-dose regimen because of toxicity or patient refusal. study. 23 In that randomized phase II study by the Southwest Oncology Group that compared HyperCVAD/MA with rituximab and bendamustine with rituximab (S1106 study), stem cell collection was planned and carried out after the 3rd of 4 HyperCVAD/MA cycles.
The R-HyperCVAD/MA arm was prematurely closed as a result of failure of stem cell collection and/or delay of therapy because of hematological toxicity. 23 Percentage (84%) of collected PBSC in the present study was higher than that (66%) reported in the alternating R-CHOP/R-DHAP regimen in the European MCL Network phase III study. 10 PFS and OS at 5 years for patients who received LEED therapy followed by ASCT were relatively higher than those for patients who did not receive LEED therapy followed by ASCT for any reason, although the comparison is difficult because of the small sample size and because it was a subset analysis according to outcome. ALT, alanine aminotransferase; AST, aspartate aminotransferase; CTCAE, common terminology criteria for adverse events; G, grade; GGT, gammaglutamyl transpeptidase; -, not applicable.
comparable to the 3% of such patients reported in the Nordic MCL-2 study 8 and the 6.7% of such patients reported in the GELA study. enrolled patients developed renal insufficiency in the GELA study during which they were treated with DHAP using cisplatin. 18 In the present study, a very good OS at 5 years of 95.2% (95%CI 70.7-99.3%) in low-risk group (N=21), and a very poor OS of 0% in high-risk group (N=2) were also observed when risk group was stratified according to MIPI-c.
Last, the incorporation of new molecular targeted drugs into the current standard regimens is an attractive approach to improving the efficacy of treatment strategies for MCL patients. It has been reported that Bruton's tyrosine kinase inhibitors and phosphoinositide 3-kinase inhibitors showed high efficacy in relapsed or refractory MCL patients. 25 Further improvements of our regimen, including more efficient harvest of auto-PBSC and/or incorporation of promising new molecular targeting agents, are important future goals.
In conclusion, R-High-CHOP/CHASER including HDAC and rituximab followed by LEED HDC with ASCT showed a high CR rate and durable PFS and OS in patients aged 65 years or younger with newly diagnosed advanced MCL. This regimen compares favorably with other regimens including HDAC, rituximab, and HDC with ASCT and can now be considered a standard treatment option for newly diagnosed younger patients with MCL.
